Moderna, Inc. (MRNA) vs Royalty Pharma PLC (RPRX)

Moderna, Inc. and Royalty Pharma PLC are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $78.8B against $34.4B — 2.3× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; Royalty Pharma PLC trades at 40.1×. Royalty Pharma PLC grew revenue faster over the last twelve months: 10.0% against −27.6%. Royalty Pharma PLC has the higher net margin (32.0% vs −141.4%) and the higher return on invested capital (5.28% vs −93.5%). Across the 19 metrics below, Royalty Pharma PLC leads on 14 and Moderna, Inc. on 5.